Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes, sparking a fresh battle for sales in a fiercely competitive market.
Novartis exercised its option to acquire Selexys Pharmaceuticals based on the SUSTAIN Phase II clinical trial of SelG1, an anti-P-selectin antibody.
Gilead Sciences announced top-line results from two Phase III clinical trials with mixed results for the Janus kinase (JAK) inhibitor momelotinib.
Episodic migraine sufferers reported fewer debilitating headaches per month after using Amgen and Novartis’ investigational drug erenumab, compared to trial participants who got a placebo.
Puma Biotechnology shares plummeted after the company disclosed patients taking its experimental breast cancer drug neratinib may require a second drug to prevent serious diarrhea.
Pfizer won approval from the European Union for its best-selling breast cancer drug Ibrance, making it the first medicine of its kind to reach the European market.
The reality of a President-elect Donald Trump has been a shot in the arm for pharma and biotech leaders’ stock prices as they surged in U.S. and European markets.
Four patients have suffered serious adverse events in a clinical trial of an experimental hemophilia medicine from Roche, the Swiss group said, clouding prospects for its potential blockbuster product.
Investors were not particularly happy with Gilead’s Q3 2016 report. In addition to sagging sales and revenue, it outlined a laundry list of failed clinical trials.